Drug-induced myoclonus: a French pharmacovigilance database study

Neurophysiologie Clinique

Volumn 36, Issue 5-6, 2006, Pages 333-336

  Brefel Courbon, C ^a,b,c   Gardette, V ^a,b   Ory, F ^c   Montastruc, J L ^a,b  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c CHU PURPAN   (France)

Author keywords

Drug induced myoclonus; Pharmacovigilance

Indexed keywords

AMANTADINE; ANESTHETIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; FENTANYL; FLUOXETINE; HALOPERIDOL; HYDROCODONE; IMIPRAMINE; LITHIUM; METOCLOPRAMIDE; MORPHINE; NEUROLEPTIC AGENT; OLANZAPINE; OPIATE DERIVATIVE; PHENYTOIN; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; UNINDEXED DRUG; VALPROIC ACID;

ARTICLE; COMORBIDITY; DRUG EFFECT; DRUG SURVEILLANCE PROGRAM; FRANCE; HUMAN; MYOCLONUS; NEUROLOGIC DISEASE; SEROTONIN SYNDROME;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; CAUSALITY; COMORBIDITY; DATABASES, FACTUAL; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; MYOCLONUS; NERVOUS SYSTEM DISEASES; PHARMACEUTICAL PREPARATIONS;

EID: 33847306870     PISSN: 09877053     EISSN: 17697131     Source Type: Journal    
DOI: 10.1016/j.neucli.2006.12.003     Document Type: Article

References (25)

1. Aguglia U., Gambardella A., Zappia M., Valentino P., and Quattrone A. Negative myoclonus during valproate-related stupor. Neurophysiological evidence of a cortical non-epileptic origin. Electroencephalogr. Clin. Neurophysiol. 94 (1995) 103-108
2. Asconape J., Diedrich A., and DellaBadia J. Myoclonus associated with the use of gabapentin. Epilepsia 41 (2000) 479-481
3. Begaud B., Evreux J.C., Jouglard J., and Lagier G. Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France. Therapie 40 (1985) 111-118
4. Begaud B., Martin K., Haramburu F., and Moore N. Rates of spontaneous reporting of adverse drug reactions in France. JAMA 288 (2002) 1588
5. Bharucha K.J., and Sethi K.D. Complex movement disorders induced by fluoxetine. Mov. Disord. 11 (1996) 324-326
6. Camacho A., Garcia-Navarro M., Martinez B., Villarejo A., and Pomares E. Olanzapine-induced myoclonic status. Clin. Neuropharmacol. 28 (2005) 145-147
7. Edwards I.R., and Aronson J.K. Adverse drug reactions: definitions, diagnosis and management. Lancet 356 (2000) 1255-1259
8. Food and Drug Administration, HHS International Conference on Harmonisation; guidance on Addendum to E2C Clinical Safety Data Management: periodic safety update reports for marketed drugs. Fed Regist. 69 (2004) 5551-5552
9. Fukuzako H., Tominaga H., Izumi K., Koja T., Nomoto M., Hokazono Y., Kamei K., Fujii H., Fukuda T., and Matsumoto K. Postural myoclonus associated with long-term administration of neuroleptics in schizophrenic patients. Biol. Psychiatry 15 27 (1990) 1116-1126
10. Garvey M.J., and Tollefson G.D. Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch. Gen. Psychiatry 44 (1987) 269-272
11. Gordon M.F. Toxin and drug-induced myoclonus. In: Fahn S., et al. (Ed). Myoclonus and paroxysmal dyskinesias, advances in neurology (2002), Lippincott Williams and Wilkins, Philadelphia 49-76 (89)
12. Jimenez-Jimenez F.J., Puertas I., and de Toledo-Heras M. Drug-induced myoclonus: frequency, mechanisms and management. CNS Drugs 18 (2004) 93-104
13. Klawans H.L., Goetz C., and Bergen D. Levodopa-induced myoclonus. Arch. Neurol. 32 (1975) 330-334
14. Lu C.S., and Chu N.S. Acute dystonic reaction with asterixis and myoclonus following metoclopramide therapy. J. Neurol. Neurosurg. Psychiatry 51 (1988) 1002-1003
15. Luquin M.R., Scipioni O., Vaamonde J., Gershanik O., and Obeso J.A. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov. Disord. 7 (1992) 117-124
16. Marconi R., Lefebvre-Caparros D., Bonnet A.M., Vidailhet M., Dubois B., and Agid Y. Levodopa-induced dyskinesias in Parkinson's disease phenomenology and pathophysiology. Mov. Disord. 9 (1994) 2-12
17. Mason P.J., Morris V.A., and Balcezak T.J. Serotonin syndrome. Presentation of 2 cases and review of the literature. Medicine 79 (2000) 201-209
18. Matsunaga K., Uozumi T., Qingrui L., Hashimoto T., and Tsuji S. Amantadine-induced cortical myoclonus. Neurology 23 56 (2001) 279-280
19. Nausieda P.A., Weiner W.J., Kaplan L.R., Weber S., and Klawans H.L. Sleep disruption in the course of chronic levodopa therapy: an early feature of the levodopa psychosis. Clin. Neuropharmacol. 5 (1982) 183-194
20. Onofrj M., Thomas A., Iacono D., Di Iorio A., and Bonanni L. Switch-over from tolcapone to entacapone in severe Parkinson's disease patients. Eur. Neurol. 46 (2001) 11-16
21. Sajatovic M., and Meltzer H.Y. Clozapine-induced myoclonus and generalized seizures. Biol Psychiatry 1 39 (1996) 367-370
22. Tandberg E., Larsen J.P., and Karlsen K. A community-based study of sleep disorders in patients with Parkinson's disease. Mov. Disord. 13 (1998) 895-899
23. Thiessard F., Roux E., Miremont-Salame G., Fourrier-Reglat A., Haramburu F., Tubert-Bitter P., et al. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001). Drug Saf. 28 (2005) 731-740
24. Vardi J., Glaubman H., Rabey J.M., and Streifler M. Myoclonic attacks induced by l-dopa and bromocryptin in Parkinson patients: a sleep EEG study. J. Neurol. 218 (1978) 35-42
25. World Health Organization Collaborating Centre for International drug monitoring. Definitions-serious, severe reactions. OMS Report 23 (1993) 19-93 (letter)